Goldman Sachs Group Inc Oyster Point Pharma, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$7.95 - $11.68 $615,528 - $904,324	-77,425 Reduced 80.92%	18,261 $203,000
Q4 2022 Feb 13, 2023	SELL	$7.95 - $11.68 $615,528 - $904,324	-77,425 Reduced 80.92%	18,261 $203,000
Q3 2022 May 14, 2024	SELL	$4.41 - $8.38 $670 - $1,273	-152 Reduced 0.16%	95,686 $538,000
Q3 2022 Nov 10, 2022	SELL	$4.41 - $8.38 $670 - $1,273	-152 Reduced 0.16%	95,686 $0
Q2 2022 May 14, 2024	BUY	$3.6 - $11.2 $345,016 - $1.07 Million	95,838 New	95,838 $415,000
Q2 2022 Aug 15, 2022	SELL	$3.6 - $11.2 $3,740 - $11,636	-1,039 Reduced 1.07%	95,838 $415,000
Q1 2022 May 16, 2022	SELL	$8.58 - $17.65 $192,603 - $396,207	-22,448 Reduced 18.81%	96,877 $1.13 Million
Q4 2021 Feb 14, 2022	BUY	$10.17 - $18.96 $963,241 - $1.8 Million	94,714 Added 384.84%	119,325 $2.18 Million
Q3 2021 Nov 10, 2021	BUY	$11.67 - $18.07 $287,210 - $444,720	24,611 New	24,611 $292,000

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.